David Colcher
Overview
Explore the profile of David Colcher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
1453
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Bzymek K, Puckett J, Zer C, Xie J, Ma Y, King J, et al.
Nat Commun
. 2018 Apr;
9(1):1580.
PMID: 29679060
Because monoclonal antibodies (mAbs) have exceptional specificity and favorable pharmacology, substantial efforts have been made to functionalize them, either with potent cytotoxins, biologics, radionuclides, or fluorescent groups for therapeutic benefit...
12.
Caserta E, Chea J, Minnix M, Poku E, Viola D, Vonderfecht S, et al.
Blood
. 2018 Jan;
131(7):741-745.
PMID: 29301755
As a growing number of patients with multiple myeloma (MM) respond to upfront therapies while eventually relapsing in a time frame that is often unpredictable, attention has increasingly focused on...
13.
Wong P, Li L, Chea J, Delgado M, Poku E, Szpikowska B, et al.
Cancer Biother Radiopharm
. 2017 Sep;
32(7):247-257.
PMID: 28910151
The blood clearance of chemotherapeutic drugs such as doxorubicin (Dox) can be extended by incorporation into lipid nanoparticles (LNPs) and further improved by tumor targeting with antibody fragments. We used...
14.
Cahan B, Leong L, Wagman L, Yamauchi D, Shibata S, Wilzcynski S, et al.
Cancer Biother Radiopharm
. 2017 Sep;
32(7):258-265.
PMID: 28910150
Objectives: Report the feasibility, toxicities, and long-term results of a Phase I/II trial of Y-labeled anticarcinoembryonic antigen (anti-CEA) (cT84.66) radioimmunotherapy (RIT), gemcitabine, and hepatic arterial infusion (HAI) of fluorodeoxyuridine (FUdR)...
15.
Wong P, Li L, Chea J, Delgado M, Crow D, Poku E, et al.
Nucl Med Biol
. 2017 Jan;
47:62-68.
PMID: 28126683
Introduction: Single chain (scFv) antibodies are ideal targeting ligands due to their modular structure, high antigen specificity and affinity. These monovalent ligands display rapid tumor targeting but have limitations due...
16.
Sta Maria N, Barnes S, Weist M, Colcher D, Raubitschek A, Jacobs R
PLoS One
. 2015 Nov;
10(11):e0142767.
PMID: 26556731
Natural killer (NK) cells play a vital antitumor role as part of the innate immune system. Efficacy of adoptive transfer of NK cells depends on their ability to recognize and...
17.
Ding H, Carlton M, Povoski S, Milum K, Kumar K, Kothandaraman S, et al.
Bioconjug Chem
. 2013 Nov;
24(11):1945-54.
PMID: 24175669
The tumor-associated glycoprotein-72 (TAG-72) antigen is highly overexpressed in various human adenocarcinomas and anti-TAG-72 monoclonal antibodies, and fragments are therefore useful as pharmaceutical targeting vectors. In this study, we investigated...
18.
Povoski S, Davis P, Colcher D, Martin Jr E
Expert Rev Mol Diagn
. 2013 May;
13(4):315-9.
PMID: 23638813
No abstract available.
19.
Ng T, Wert D, Sohi H, Procissi D, Colcher D, Raubitschek A, et al.
Clin Cancer Res
. 2013 Mar;
19(9):2518-27.
PMID: 23532891
Purpose: Targeted nanotherapies are being developed to improve tumor drug delivery and enhance therapeutic response. Techniques that can predict response will facilitate clinical translation and may help define optimal treatment...
20.
Yazaki P, Lee B, Channappa D, Cheung C, Crow D, Chea J, et al.
Protein Eng Des Sel
. 2012 Nov;
26(3):187-93.
PMID: 23175797
A series of anti-tumor/anti-chelate bispecific antibody formats were developed for pre-targeted radioimmunotherapy. Based on the anti-carcinoembryonic antigen humanized hT84.66-M5A monoclonal antibody and the anti-DOTA C8.2.5 scFv antibody fragment, this cognate...